TY - JOUR
T1 - A polyphenolic complex attenuates inflammatory response and bloodbrain barrier disruption
AU - Bian, Yuting
AU - Yamashita, Toru
AU - Taira, Yuki
AU - Shang, Jingwei
AU - Tsunoda, Keiichiro
AU - Feng, Tian
AU - Sasaki, Ryo
AU - Liu, Xia
AU - Shi, Xiaowen
AU - Tadokoro, Koh
AU - Nomura, Emi
AU - Matsumoto, Namiko
AU - Osakada, Yusuke
AU - Omote, Yosio
AU - Takemoto, Mami
AU - Hishikawa, Nozomi
AU - Ohta, Yasuyuki
AU - Abe, Koji
N1 - Funding Information:
This work was partly supported by a Grant-in-Aid for Scientific Research with grant no. (B) 17H04196, (C) 17K10827 and Challenging Research (Grant no. 15K15527), and by Grants-in-Aid from the Research Committees (Mi-zusawa H, Nishizawa M, Sasaki H, and Aoki M) from the Ministry of Health, Labour and Welfare of Japan.
PY - 2020
Y1 - 2020
N2 - Background: Cerebral ischemia causes a strong inflammatory response. Neumentix is a dietary supplement containing 14.9% rosmarinic acid and 29.9% total phenolic content, which has been proved to be beneficial against inflammatory response. Therefore, Neumentix’s effect on anti-inflammatory and blood brain barrier (BBB) disruption in transient middle cerebral artery occlusion (tMCAO) model mice is investigated in this study. Methods: After the pretreatment of vehicle or Neumentix 134 mg/kg/d, intraperitoneal injection (i.p.) (containing rosmarinic acid 20 mg/kg/d) for 14 days, mice were subjected to tMCAO for 60 min and kept receiving vehicle or Neumentix daily 5 days afterward. Results: Neumentix treatment ameliorated neurobehavioral impairment in the corner test (5d after tMCAO, **P<0.01), reduced infarct volume (# P<0.05), suppressed expression of ionized calciumbinding adapter molecule-1 (Iba-1), tumor necrosis factor alpha (TNF-α) and monocyte chemoattractant protein-1 (MCP-1) (### P<0.001), and improved the integrity of BBB (§ P<0.05) at 5 days after tMCAO. Conclusion: The present study provided an evidence of Neumentix’s anti-inflammatory and neuroprotection effect against BBB disruption on experimental tMCAO model mice, suggesting that Neumentix could be a potential therapeutic agent for stroke.
AB - Background: Cerebral ischemia causes a strong inflammatory response. Neumentix is a dietary supplement containing 14.9% rosmarinic acid and 29.9% total phenolic content, which has been proved to be beneficial against inflammatory response. Therefore, Neumentix’s effect on anti-inflammatory and blood brain barrier (BBB) disruption in transient middle cerebral artery occlusion (tMCAO) model mice is investigated in this study. Methods: After the pretreatment of vehicle or Neumentix 134 mg/kg/d, intraperitoneal injection (i.p.) (containing rosmarinic acid 20 mg/kg/d) for 14 days, mice were subjected to tMCAO for 60 min and kept receiving vehicle or Neumentix daily 5 days afterward. Results: Neumentix treatment ameliorated neurobehavioral impairment in the corner test (5d after tMCAO, **P<0.01), reduced infarct volume (# P<0.05), suppressed expression of ionized calciumbinding adapter molecule-1 (Iba-1), tumor necrosis factor alpha (TNF-α) and monocyte chemoattractant protein-1 (MCP-1) (### P<0.001), and improved the integrity of BBB (§ P<0.05) at 5 days after tMCAO. Conclusion: The present study provided an evidence of Neumentix’s anti-inflammatory and neuroprotection effect against BBB disruption on experimental tMCAO model mice, suggesting that Neumentix could be a potential therapeutic agent for stroke.
KW - Anti-inflammation
KW - Blood brain barrier
KW - Ischemic stroke
KW - Middle cerebral artery occlusion
KW - Polyphenolic complex
KW - Rosmarinic acid
UR - http://www.scopus.com/inward/record.url?scp=85084759395&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85084759395&partnerID=8YFLogxK
U2 - 10.2174/1567202617666200517105727
DO - 10.2174/1567202617666200517105727
M3 - Article
C2 - 32416676
AN - SCOPUS:85084759395
SN - 1567-2026
VL - 17
SP - 286
EP - 293
JO - Current Neurovascular Research
JF - Current Neurovascular Research
IS - 3
ER -